BHCM
GLUE icon

Brevan Howard Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Brevan Howard Capital Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,323
Closed -$209K – 2265
2025
Q4 		$209K Sell
13,323
-33,589
-72% -$453K ﹤0.01% 1560
2025
Q3 		$348K Buy
46,912
+11,165
+31% +$59.1K ﹤0.01% 1486
2025
Q2 		$161K Sell
35,747
-1,827
-5% -$8.15K ﹤0.01% 1746
2025
Q1 		$174K Buy
+37,574
New +$230K ﹤0.01% 1003

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Brevan Howard Capital Management's GLUE Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Monte Rosa Therapeutics (GLUE) in Q1 2026, closing a stake of 13,323 shares — an estimated $209K sold.

Brevan Howard Capital Management first reported a position in GLUE in Q1 2025 and held it in 4 quarters. The position peaked at $348K in Q3 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining Monte Rosa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 13,323 Monte Rosa Therapeutics shares in Q1 2026, an estimated $209K.
  • Brevan Howard Capital Management first reported a position in Monte Rosa Therapeutics in Q1 2025 and held it in 4 quarters.
  • Brevan Howard Capital Management's Monte Rosa Therapeutics position peaked at $348K in Q3 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.